::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

CLINICAL EFFICACY OF PAROXETINE IN COMBINATION WITH OLANZAPINE TO TREAT SCHIZOPHRENIA

AUTHORS:

Dr Ayesha Javed, Dr Ujala Shahid, Dr Muhammad Asad Asif

ABSTRACT:

Objective: To examine the clinical effectiveness of paroxetine in combination with olanzapine for the treatment schizophrenia along with depression. Methodology: A sum of 60 elderly patients of schizophrenia with depression who got admission in hospital from May 2018 to March 2020 were the participants of this research work and we randomly divided these subjects into OG (Observation Group) and CG (Control Group) with the use of the random number table, with 30 patients in every group. We treated the patients of CG with olanzapine orally, whereas the patients of CG got treatment with olanzapine in combination with paroxetine orally. Level of Hcy (Homocysteine) in the patients of both groups was examined prior and after the treatment. HAMD (Hamilton Depression) score and PANSS (Positive & Negative Symptoms Scale) were in use for the evaluation of the efficacy of the treatment. We also compared the adverse effects of the treatment on the patients of both groups. Results: After the treatment, Hcy level in serum in the patients of OG was much lower as compared to the patients of CG (P<0.050), and it was very close to the normal values. We found no difference in the PANSS score between the patients of both groups before the start of treatment (P>0.050). After the completion of treatment, PANSS and negative factor scores in the patients of OG were much low as compared to the patients of CG and this difference was much significant statistically (P<0.050). There was no significant difference in the HAMD score in the patients of both groups before treatment (P>0.050). After the treatment, HAMD scores of the patients of OG was much low as compared to the patients of CG (P<0.050). There was no significant difference in the prevalence of adverse reactions between the patients of both groups (P>0.050). Conclusion: Paroxetine in combination with olanzapine has a positive clinical impact on the treatment of schizophrenia present along with depression. It can efficiently decrease the Hcy level in serum, relieve schizophrenia’s symptoms and lessen the depressive symptoms present in patients, with much high safety. KEYWORDS: Depression, Olanzapine, Efficacy, Paroxetine, Observation Group, Control Group.